News & Updates

The use of anticoagulant therapy offers no survival benefit in patients with pulmonary arterial hypertension (PAH), a recent study has shown.

Researchers at the University of Hong Kong (HKU) have found that the risk of ischaemic stroke is not increased in patients on proton-pump inhibitor (PPI) monotherapy, but is increased in those coprescribed with antithrombotic drugs, possibly due to their underlying higher risk profiles.

The old immunomodulatory drug antithymocyte globulin (ATG), administered at a low dose, can safely reduce the loss of beta-cell function in young people with recent-onset type 1 diabetes (T1D), as shown in the phase II MELD-ATG trial.

Adding liver-directed radiation therapy (RT) to atezolizumab and bevacizumab (A/B) produces limited additional toxicity with higher response rates among patients with hepatocellular carcinoma (HCC), reports a recent study. However, substantial differences in baseline characteristics hinder a full interpretation of this data.

The use of antioxidant supplements in men seeking fertility care does not appear to increase the chances of conceiving for their female partners, as shown in the multicentre SUMMER trial.

A recent study has shown infliximab’s superiority over adalimumab in the treatment of bio-naïve patients with fistulizing Crohn’s disease (FCD). However, there is no therapeutic difference seen in bio-exposed FCD.

Treatment with the novel cannabinoid receptor 1 (CB1R) inverse agonist monlunabant appears to yield significant and clinically meaningful weight loss in adults with obesity and metabolic syndrome, according to a phase IIa trial.